| GAG | glycosaminoglycan; group-specific antigen gene |
|---|---|
| GAS | galactorrhea-amenorrhea syndrome; gastric acid secretion; gastrin; gastroenterology; general adaptat... |
| gp | gene product; glycoprotein; group |
| GTA | gene transfer agent; Glanzmann thrombasthenia; glycerol teichoic acid |
| HGM | hog gastric mucosa; human gene mapping; human glucose monitoring |
| triple response | <immunology> The vascular changes in the skin in response to mild mechanical injury, an outward spreading zone of reddening flare) followed rapidly by a weal (swelling) at the site of injury. Redness, heat and swelling, three of the cardinal signs of inflammation, are present. (18 Nov 1997) |
|---|---|
| evoked response | An alteration in the electrical activity of a region of the nervous system through which an incoming sensory stimulus is passing; may be somatosensory (SER), auditory (BAER), or visual (VER). See: evoked potential. (05 Mar 2000) |
| evoked response audiometry | A type of electrophysiologic audiometry in which electrical potentials of neural impulses from the cochlear nerve and various levels in the brain in response to acoustic stimulation are used to localise the site of a lesion causing a hearing loss. (05 Mar 2000) |
| unconditioned response | A response, such as salivation, which is a part of the animal or human repertoire. Compare: conditioned response. (05 Mar 2000) |
| flight or fight response | See: emergency theory. (05 Mar 2000) |
| late-phase response | Recurrence of symptoms after an appreciable interval following challenge with an antigen; preceded by an initial early-phase response. (05 Mar 2000) |
| lh response to gnrh | This test measures the level of luteinising hormone in the blood after an injection of gonadotrophin releasing hormone (GNRH), normally produced in the hypothalamus. This will test the ability of the pituitary gland to respond by measuring one of the pituitary glands byproducts, luteinising hormone. This test is used to differentiate hypogonadism (ovary or testes) into primary hypogonadism (problem is with the ovary or testes) or secondary hypogonadism (problem is with the pituitary gland or the hypothalamus). (27 Sep 1997) |
| lymphoproliferative response | <haematology, immunology> A specific immune response that entails rapid T-cell replication. Standard antigens, such as tetanus toxoid, that elicit this response are used in lab tests of immune competence. (13 Nov 1997) |
| allelic gene | See: allele, dominance of traits. (05 Mar 2000) |
| antibiotic resistance gene | Genes in a microorganism which confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, or by being a mutant form of the antibiotic's target so that it can ignore it. (09 Oct 1997) |
| autosomal gene | A gene located on any chromosome other than the sex chromosomes (X or Y). (05 Mar 2000) |
| bicoid gene | A group of genes which are important to the proper development of the head and thorax in the embryo of the fruit fly Drosophila melanogaster. (09 Oct 1997) |
| BRCA1 breast cancer susceptibility gene | This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer. (12 Dec 1998) |
| calcitonin gene-related peptide | <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response. It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator. Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion. Acronym: CGRP (05 May 2002) |
| cancer susceptibility gene | tumour suppressor gene |